Daixi Lin
Overview
Explore the profile of Daixi Lin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feng S, Liang L, Shen C, Lin D, Li J, Lyu L, et al.
Mol Ther Nucleic Acids
. 2022 Aug;
29:354-367.
PMID: 35950213
A sharp increase in multidrug-resistant tuberculosis (MDR-TB) threatens human health. Spontaneous mutation in essential gene confers an ability of resistance to anti-TB drugs. However, conventional laboratory strategies for identification and...
2.
Liang L, Lin D, Chen Y, Li J, Liang W, Zhao H, et al.
mSystems
. 2022 May;
7(3):e0020922.
PMID: 35615956
The rapid emergence of multidrug-resistant/extensively drug-resistant tuberculosis (TB) is responsible for treatment failure in patients with TB and significantly endangers global public health. Recently, bioenergetics has become a new paradigm...
3.
Feng S, Wu Z, Liang W, Zhang X, Cai X, Li J, et al.
Mol Biol Evol
. 2022 Apr;
39(5).
PMID: 35485492
The antibiotic resistance crisis continues to threaten human health. Better predictions of the evolution of antibiotic resistance genes could contribute to the design of more sustainable treatment strategies. However, comprehensive...
4.
Feng S, Liang W, Li J, Chen Y, Zhou D, Liang L, et al.
Emerg Microbes Infect
. 2022 Apr;
11(1):1236-1249.
PMID: 35437117
The global dissemination of the mobilized colistin resistance gene, , threatens human health. Recent studies by our group and others have shown that the withdrawal of colistin as a feed...
5.
Yang F, Xu L, Liang L, Liang W, Li J, Lin D, et al.
Front Microbiol
. 2021 Dec;
12:774492.
PMID: 34956138
Type I and type II CRISPR-Cas systems are employed to evade host immunity by targeting interference of bacteria's own genes. Although (), the causative agent of tuberculosis, possesses integrated type...